Skip to main content
Hit enter to search or ESC to close
Close Search
Menu
Company
Team
Psybrary™
Pipeline
Investors
Investor Overview
Press Releases
Media Coverage
Events + Presentations
Stock Information
SEC Filings
Corporate Governance
News Alerts
Contact
twitter
facebook
linkedin
Investors
Press Releases
NASDAQ: ENVB
Overview
Press Releases
Media Coverage
Events + Presentations
Stock Information
SEC Filings
Corporate Governance
News Alerts
Press Releases
Enveric Biosciences CEO, David Johnson, Issues Letter to Shareholders
August 18, 2021
Enveric Biosciences Announces Approval from Israel’s Ministry of Health to Begin its Phase 1/2 Trial of Triple-Combination CBD Treatment for Glioblastoma
July 8, 2021
Enveric Biosciences and MagicMed to Participate in June 2021 Investor and Industry Conferences
June 3, 2021
Enveric Biosciences Announces Definitive Agreement to Acquire MagicMed Industries, a Pharmaceutical Drug Discovery and Development Platform Focused on New-Generation Psychedelic Molecular Compounds and Derivatives
May 24, 2021
Enveric Biosciences Reports First Quarter 2021 Financial Results
May 18, 2021
Enveric Biosciences Appoints Dr. Arash Asher to Scientific Advisory Board
May 12, 2021
Enveric Biosciences to Participate in the Planet MicroCap Showcase on April 21st
April 14, 2021
Enveric Biosciences Appoints Carter Ward as Chief Financial Officer
April 12, 2021
Enveric Biosciences Reports Full Year 2020 Financial Results and Provides Shareholder Update on its Accomplishments in 2021
April 1, 2021
Enveric Biosciences Appoints Dr. Douglas D. Lind to Company’s Board of Directors
March 18, 2021
‹
1
…
11
12
13
14
›
Close Menu
Company
Team
Psybrary™
Pipeline
Investors
Investor Overview
Press Releases
Media Coverage
Events + Presentations
Stock Information
SEC Filings
Corporate Governance
News Alerts
Contact
twitter
facebook
linkedin